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Abstract
Background: This study aimed to investigate existing trialling activity relating to three antipsychotic drugs from
the WHO List of Essential Medicines (chlorpromazine, fluphenazine decanoate, haloperidol), link existing trials to
existing Cochrane reviews, identify gaps in reviewing activity on accessible treatments for people with
schizophrenia.
Methods: We used the Cochrane Schizophrenia Group’s register searching for all studies comparing the three
antipsychotic drugs with each other and with all other pharmacological interventions listed on the Essential
Medicines List (with the addition of ‘placebo or no drug’). For each we also considered studies that focussed on
administration, dose, withdrawal and use of that drug in specific circumstances administration. Data were then
extracted on a number of studies, number of participants within those studies, and as to whether a maintained
review already exists. Finally, every effort was made to consider as to whether there were possibilities for missing
comparisons that no one had ever investigated.
Results: There has been considerable research activity involving the three ‘essential’ antipsychotics and also
comparing those three drugs to others on the ‘essential’ list. We found 490 studies with 77957 participants for
haloperidol, 316 studies with 29179 participants for chlorpromazine and 33 studies with 4503 participants for
fluphenazine decanoate. Reviewing activity has also been considerable in this area but there are notable omissions
which would necessitate new reviews to comprehensively cover the area.
Conclusions: We have used the ‘sample frame’ of the WHO Essential drug list as a starting point. WHO prioritises
for us those drugs that have universal accessibility but they may not be the compounds that are first choice if
others are available. It is encouraging to see how many maintained reviews already exist to service those
undertaking WHO guidelines. The needs of those guiding care can be taken as a means of prioritising research. For
largest global impact WHO Essential Medicine list provides clear direction. By using this technique workload can be
anticipated, prioritising can take place for new reviews and updates.
Background
The Cochrane Collaboration is a unique organisation
producing as well as maintaining systematic reviews,
mostly focussed on the effects of healthcare interven-
tions [1]. These reviews are regularly maintained in the
light of new evidence or valid criticism. The Cochrane
Library has been shown to contain the highest grade
reviews of any publication [2].
With the enormous task of summarising the effects of
all healthcare interventions (and maintaining those
summaries) it is a logistical, ethical and moral dilemma
where to focus efforts. Prioritising in the midst of so
much of a ‘confusion of evidence’ has, for some time,
troubled the Collaboration as a whole [3].
Mental health is no exception. The randomised con-
trolled trial is the most powerful means of evaluating
mental health treatments [4]. The five mental health
Cochrane groups currently produce and maintain 512
reviews on the Cochrane Library but these remain a
small fraction of the potential numbers of relevance and
interest. With limited resources it is imperative that
energies are not dissipated in producing reviews that are
likely to be of little value to people with mental health
problems. A series of competing priorities often results
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any medium, provided the original work is properly cited.in continuation of the status quo - where the priorities
of reviewer, or the editorial base, take precedence over
others.
The recently produced WHO guidance on the care of
people with mental health problems offered an opportu-
nity to explore a technique for prioritisation [5]. 80% of
the world’s population with schizophrenia live in low
and middle income countries. The mainstay of treat-
ment of people with serious mental illnesses such as
schizophrenia remains antipsychotic drugs but many of
these drugs are unavailable worldwide or are available
only to the rich.
WHO, have drawn up a list of drugs they designate as
‘essential’ [6]. “Essential medicines are those that satisfy
the priority health care needs of the population. They
are selected with due regard to public health relevance,
evidence on efficacy and safety, and comparative cost-
effectiveness. Essential medicines are intended to be
available within the context of functioning health sys-
tems at all times in adequate amounts, in the appropri-
ate dosage forms, with assured quality and adequate
information, and at a price the individual and the com-
munity can afford.”[6] This list includes over 350 medi-
cines of which twelve are for mental and behavioural
disorders: amitriptyline and fluoxetine for depressive
disorder; carbamazepine, lithium carbonate and valproic
acid for bipolar disorder, diazepam for anxiety disorder;
clomipramine for obsessive-compulsive disorder; nico-
tine replacement therapy and methadone for disorders
due to psychoactive substance use. The list includes
only three drugs for psychotic disorder: chlorpromazine,
haloperidol, and fluphenazine decanoate.
In these years several applications have been sub-
mitted to WHO to include other drugs in the Essential
List of Medicine. The list of r e j e c t e dd r u g si n c l u d e s5 1
pharmacological interventions of which 12 are psycho-
tropic drugs (6 antipsychotics, 4 antidepressants, 1
anticonvulsant, 1 benzodiazepine) [7]. The reasons for
rejection are not clear. Regarding antipsychotics, for
example, Clozapine is mentioned in the WHO Interven-
tion guide [5] for “treatment resistant schizophrenia”
(those who have not responded to other antipsychotic
agents at adequate dosages for adequate duration) but,
nevertheless, appears in the rejected drugs list. Rejection
could be from a series of factors such as evidence, cost,
distribution, or/and ease of use.
In 2010, those drawing up the guidance for WHO
contracted the Cochrane Schizophrenia Group to pro-
duce summaries of the findings of reviews relevant to
these drugs, using the Grading of Recommendations,
Assessment, Development and Evaluation (GRADE)
approach [8]. This methodology is suitable for summar-
izing the evidence extracted from systematic reviews
and meta-analyses into ‘’Summary of Findings (SoF)
tables’’; grading the quality of evidence summarized in
SoF tables; and grading the strength of treatment
recommendations [9].
This resulted in approximately forty summaries of
findings from existing best evidence in Cochrane
reviews. It also highlighted the possibility that some use-
ful data may not have been systematically reviewed and
therefore were not available to policy makers with global
impact.
Aims
To use WHO ‘essential’ antipsychotic drugs as a sam-
pling frame, investigate existing trialling activity relating
to each of these antipsychotic drugs, link existing trials
to existing Cochrane reviews. We aim at identifying
gaps in reviewing activity on accessible treatments for
people with schizophrenia, in order to prioritise
Cochrane reviews using the needs of WHO.
Methods
We used the Cochrane Schizophrenia Group’sr e g i s t e r
that contains 16,000 citations to approximately 13,000
studies. This register is complied of regular searching of
71 databases and is considerably more comprehensive
that can be found either on Medline, PsycInfo, EMBase,
or even the Cochrane Central Register of Trials [10].
This represents the most comprehensive register of sub-
ject-specific trials in existence. These studies are reliably
indexed [11] regarding the intervention and the number
of participants.
MP systematically searched the register for all studies
comparing the three antipsychotic drugs with each other
and with all other pharmacological interventions listed
on the Essential Medicines List (with the addition of the
intervention of ‘p l a c e b oo rn od r u g ’). For each we also
considered studies that focussed on administration,
dose, withdrawal and use of that drug in specific cir-
cumstances administration.
Data were then extracted on a number of studies,
number of participants within those studies, and as to
whether a maintained review already exists. Finally,
every effort was made to consider as to whether there
were possibilities for missing comparisons that no one
had ever investigated.
Results
There has been considerable research activity involving the
three ‘essential’ antipsychotics (Table 1) and also compar-
ing those three drugs to others on the ‘essential’ list (Table
2). We found a total of 490 studies with 77957 participants
for haloperidol, 316 studies with 29179 participants for
chlorpromazine and 33 studies with 4503 participants for
fluphenazine decanoate. Reviewing activity has also been
considerable in this area but there are notable omissions
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Discussion
We have used the ‘sample frame’ of the WHO Essential
drug list as a starting point. WHO prioritises for us
those drugs that have universal accessibility but they
may not be the compounds that are first choice if others
are available. Also, we have not considered comparisons
of drugs with other interventions such as psychothera-
pies, techniques of management, and other physical
treatment such as electro-convulsant therapy. Studies
relevant to these comparisons do exist and recognise
that the scope of our list of comparisons is limited.
However, these other treatments are not listed by WHO
as essential (except for treatment of every person with
respect and dignity), they are not known to be univer-
sally accessible, and they are more difficult to define for
global purposes of comparison. Confining the list to
drugs only makes this list of comparisons serviceable.
There may well be, therefore, other comparisons with
universally accessible [non-pharmacological] treatments
that we have not considered.
The key antipsychotics have been compared with
many other drugs that fall into the broad categories
seen within Table 2. We have not attempted to categor-
ise every possible combination as we did for Table 1.
Clearly researchers have undertaken many trials of treat-
ments, even if used in a less than conventional way,
using the three essential antipsychotics and compared
them with other drugs. Many of these comparisons
would seem odd or unusual but in situations where very
few alternatives exist some less conventional alternative
treatments may be considered. These have been much
less commonly considered by reviewers and this exercise
has highlighted that some should be the focus of reviews
of the future.
It is encouraging to see how many maintained reviews
already exist to service those undertaking WHO guide-
lines. This effort has been because of the foresight of
reviewers, editors and sometimes funders (for the larger
of the reviews). Most reviews, however, are not fully up-
Table 1 WHO three essential antipsychotics and possible comparisons
RCTs Total number of people Cochrane review Reference Up to date?
Chlorpromazine
vs fluphenazine depot 7 1314 ✓ [13] ✗
vs haloperidol 51 6001 ✓ [14] ✗
vs placebo 233 19854 ✓ [15] ✗
Withdrawal 1 32 ✓ [16] ✗
Techniques of administration 8 669 ✗
Dose 15 1279 ✓ [17] ✗
In specific circumstances 1 30 ✓ [18] ✗
Fluphenazine Decanoate
vs chlorpromazine 7 1314 ✓ [13] ✗
vs haloperidol 19 2339 ✓ [13] ✗
vs placebo 4 456 ✓ [13] ✗
Withdrawal 0 0 ✗
Techniques of administration 0 0 ✗
Dose 3 394 ✗
In specific circumstances 0 0 ✗
Haloperidol
vs chlorpromazine 51 6001 ✓ [14] ✗
vs fluphenazine depot 19 2339 ✓ [13] ✗
vs placebo 237 41321 ✓ [19] ✗
Withdrawal 3 126 ✗
Techniques of administration 50 10583 ✗
Dose 126 16470 ✓ [20] ✗
In specific circumstances 4 1117 ✓ [21] ✗
RCTs: Randomized Controlled Trials
Vs: Versus
✓: Systematic Reviews or updates already exist
✗: Systematic Reviews or updates do not exist
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less active areas of research, there remains the challenge
of update. We expect that new fresh reviews meeting
the needs of WHO and updates of not fully up-to-date
reviews will be used to regularly update the WHO list
of essential medicines and other lists of medicines
included in formularies or emergency kits [12].
New techniques are being introduced to the science of
data synthesis that allow use of more of the older data
or at the very least their reconsideration. These include
more explicit and transparent evaluation of potential
risk of bias in the design of included studies, the possi-
bility to explore the diversity of the results of different
studies included in the analysis (heterogeneity), and the
possibility to summarize the results of systematic
r e v i e w sa n dm e t a - a n a l y s e si n t o‘’Summary of Findings
(SoF) tables’’.
Conclusions
The needs of those guiding care can be taken as a
means of prioritising research. For largest global impact
WHO Essential Medicine list provides clear direction.
By using this technique workload can be anticipated,
prioritising can take place for new reviews and updates.
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Table 2 WHO three essential antipsychotics and other drugs on the ‘Essential’ list (by drug class) to which they have
been compared within randomized trials
RCTs Total number of people Cochrane review Reference Up to date?
Chlorpromazine
vs anticonvulsant agents 2 118 ✗
vs antidepressants 12 732 ✓ [22,23] ✗
vs antihypertensive agents 8 286 ✗
vs antiparkinsonian agents 3 80 ✗
vs antituberculosis agents 1 25 ✗
vs barbiturates 3 750 ✗
vs benzodiazepines 9 457 ✓ [24,25] ✗
vs mood stabilizers 2 49 ✓ [26-28] ✗
vs opioid agonist 1 340 ✗
vs opioid antagonist 1 60 ✗
Fluphenazine decanoate
vs antihypertensive agents 1 17 ✗
vs antituberculosis agents 1 55 ✗
Haloperidol
vs antiarrhythmic agents 2 30 ✗
vs antidepressants 10 774 ✓ [22,23] ✗
vs antidopaminergic agents 4 146 ✗
vs antigout agents 1 46 ✗
vs antihypertensive agents 3 122 ✗
vs antineoplastic agents 3 101 ✗
vs antiparkinsonian agents 8 265 ✗
vs antiprogesterone agents 1 80 ✓ [29] ✗
vs benzodiazepines 35 4012 ✓ [24,25] ✗
vs ethanol 1 35 ✗
vs glucose 1 unclear ✗
vs mood stabilizers 23 1648 ✓ [26-28] ✗
vs stimulant agents 1 20 ✗
RCTs: Randomized Controlled Trials
Vs: Versus
✓: Systematic Reviews or update already exist
✗: Systematic Reviews or update do not exist
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